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Mass spectrometry-based proteomics has played an increas-
ing role in biological and biomedical research as gauged by
the ever increasing numbers of thousands of publications
arising each year. With advances in proteomic technol-
ogy, bioinformatics and diﬀerent experimental approaches,
sampling of near complete proteomes for some organisms,
assessment of entire signaling pathways, and discovery of
biomarkersofdiseasehavebecomepossible.Thebroadrange
and ease of implementation of various workﬂows combined
with assess to robust instrumentation has allowed for con-
tinued crossover of proteomics to many diverse biological
and even clinical areas. Here, the Journal of Biomedicine
and Biotechnology presents the “Proteomics 2011” special
issue. Although only representing a small fraction of the
contribution of mass spectrometry to many research ﬁelds,
the articles presented here deﬁnitely encompass the excite-
ment that proteomics research can provide to complement
traditional biological studies.
To start this special issue, we have ﬁve contributions
that review several aspects of proteomic research. W. Zhu
et al. discuss the diﬀerent contributing factors for accurate
label-free quantiﬁcation, while challenges that remain for
proteomic SELDI experiments to be successful in biomarker
discovery are covered by M.-P. Merville and coworkers.
Two more specialized reviews cover parts of the biology
of translation in eukaryotes mediated by internal ribosome
entry sites and intrinsically disordered protein structures
(Pecheco et al. and V. N. Uversky, resp.). Lastly, how
proteomics may play a role in crop disease prevention by
understanding the pathogenesis of fungi is covered by J. V.
Jorr´ ın-Novo and coworkers.
Articles describing the development of methods and
computational approaches are also well represented in this
special issue. On the methods side, we have J. Hou et al.
demonstrating improved MALDI-MS of phosphopeptides
by an optimized matrix. Improved sample preparations
including separations are utilized by M. Centlow et al. and
E. Gamelin and coworkers to uncover potential biomarkers
of preeclamptic placenta and to improve proteome coverage
of plasma, respectively. 2D liquid chromatography coupled
to mass spectrometry is used to determine proteomic
response to cadmium stress in plants by G. Visioli et al.
Identifying released bioactive proteins from human platelets
is addressed by G. Cagney and coworkers. Dealing with
the computational end of proteomic studies, T. H. Corzett
et al. describe statistical measures for determining variation
resultingfromquantiﬁcationofthehumanplasma proteome
separated by 2D diﬀerence gel electrophoresis. Enhanced
peptide and protein identiﬁcation is addressed by L. Pattini
andcoworkerswhopresentanovelmethodforpreprocessing
proteomic data, and by K. Macur et al. who utilize peptide
retention time as an extra indication of false positives.
Lastly, we showcase the application of mass spectrom-
etry-based proteomics for the determination of potential
biomarkers from various biological and clinical conditions.
J. Svasti and coworkers investigate the secretomes from2 Journal of Biomedicine and Biotechnology
diﬀerent carcinoma cell lines by GeLC-MS to ﬁnd potential
tumor biomarkers. In search of an elusive Downs syndrome
(DS) protein marker, S. Hahn and coworkers use iTRAQ
labeling to screen plasma from DS pregnancies. Campostrini
et al. look to quantify the iron regulating hepcidin protein
isoforms in patients aﬄicted by chronic haemodialysis.
Overall,wehopethisspecialissuebringstolightthepotential
that proteomic experiments possess and the impacts that
c o u l db em a d et oh e a l t ha n dd i s e a s e .
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